UNSPSC 51172012: Deoxycholic acid

This classification denotes a cholagogue or choleretic agent with the molecular formula C24H40O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 005990WHZZ, chemically known as 3,12-dihydroxycholan-24-oic acid but generally known as deoxycholic acid, which bears US NIH Compound Identifier 2987. European Medicines Agency schedules Deoxycholic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13541MIG. The term DEOXYCHOLIC ACID is an International Non-Proprietary Name.

Most nations schedule deoxycholic acid under HS 29181900 and SITC 51392. As of Q4 2014, DEOXYCHOLIC ACID remains the US FDA Preferred Term for this commodity. Deoxycholic acid bears US NLM identifiers UMLS ID C0011479 and NCI Concept Code C81042. SMILES: OC1C2(C(C3C(C4(C(CC3)CC(O)CC4)C)C1)CCC2C(CCC(=O)O)C)C.

UNSPSC 51172012 Deoxycholic acid is a Commodity code that maps to state and local procurement of pharmaceutical and laboratory testing supplies rather than the specific chemical compound its name suggests. Recent state and local solicitations under this code reflect procurement of broad pharmaceutical and drug-testing products—including specimen collection services, immunoassay screening, generic multi-source pharmaceuticals, and over-the-counter products distributed through authorized wholesaler networks. The issuing bodies span state health and human services commissions, county corrections and supervision departments, and multistate cooperative purchasing alliances. Work ranges from routine specimen collection and drug screening for offender populations to broader pharmaceutical supply agreements serving multiple state and local government facilities.

Activity under the code appears concentrated in Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services, with proposals due July 23, 2026, requesting staffing of two collection sites, immunoassay screening with LC/MS/MS or GC/MS confirmation, and alternative testing methodologies (oral fluid and hair testing) for approximately 25,031 annual tests; the estimated contract value is $600,000 over two years with three optional one-year renewal periods. The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendors' capacity to establish direct contracts with self-insured health plans outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, with proposals due March 26, 2026 and contract commencement July 1, 2026; evaluation weights pricing competitiveness at 75 percent, compliance and administrative requirements at 20 percent, and EDI capability at 5 percent, with awarded vendors required to maintain relationships with AmerisourceBergen Drug Corporation, Cardinal Health, or Morris & Dickson Co.